Eli Lilly, the US-based pharmaceutical major is set to open a global development centre (GDC) in Hyderabad's IT hub by mid-2025.

The facility, located near IKEA in Phoenix Equinox, spans 2.5–2.75 lakh sq. ft. and will accommodate over 2,500 employees. This move aligns with Hyderabad's rise as a significant hub for global capability centres (GCCs) in the life sciences sector.

Eli Lilly's CEO, David Ricks, had hinted at expansion plans during the BioAsia 2024 conclave, where he also met with State Industries and IT Minister, D Sridhar Babu. Other global pharma players like Amgen has already secured six lakh sq. ft. at RMZ Nexity and is exploring additional options in Genome Valley.

Meanwhile, GSK is reportedly scouting the Hyderabad market for opportunities. In 2024, Telangana's life sciences sector attracted over Rs 36,000 crore in investments, with 13 GCCs committing to establish operations in the state.It iincludes healthcare and medtech leaders such as Evernorth, HCA Healthcare, Providence, Medtronic, and Olympus Corporation, which have set up large-scale global innovation centres. 

Hyderabad’s appeal stems from its infrastructure, biotech ecosystem, and strategic investments, positioning it as a preferred destination for global pharma, biopharma, and healthcare leaders.